Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States
Sarah M. Bartsch,James A. McKinnell,Leslie E Mueller,Loren G. Miller,Shruti K. Gohil,Susan S. Huang,Bruce Y. Lee +6 more
TLDR
A CRE clinical and economics outcomes model is developed to determine the cost of CRE infection from the hospital, third-party payer, and societal, perspectives and to evaluate the health and economic burden of CRE to the USA.About:
This article is published in Clinical Microbiology and Infection.The article was published on 2017-01-01 and is currently open access. It has received 144 citations till now. The article focuses on the topics: Population.read more
Citations
More filters
Journal Article
Economics and Preventing Hospital-Acquired Infection
TL;DR: This work defines the key economic concepts and specifies an illustrative model that uses hypothetical data to identify how two related questions might be addressed: how much should be invested for infection control, and what are the most appropriate infection-control programs?
Journal ArticleDOI
Global geographic trends in antimicrobial resistance: the role of international travel.
Isabel Frost,Isabel Frost,Thomas P. Van Boeckel,Thomas P. Van Boeckel,João Pires,Jessica Craig,Ramanan Laxminarayan,Ramanan Laxminarayan +7 more
TL;DR: The role of travel in the international dissemination of antimicrobial resistance is reviewed and actions at the levels of travelers, travel medicine practitioners, and policymakers that would mitigate this threat are considered.
Journal ArticleDOI
Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study.
Eilish McCann,Arjun Srinivasan,C Andrew DeRyke,Gang Ye,Daryl D. DePestel,John Murray,Vikas Gupta +6 more
TL;DR: Widespread infection prevention and antimicrobial stewardship initiatives, in combination with new treatment options, may be required to reduce the burden of carbapenem resistance in health care settings.
Journal ArticleDOI
A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
TL;DR: Plazomicin demonstrated microbiological and clinical success and an overall safety profile supportive of further clinical development, and was evaluated in adults with cUTI or acute pyelonephritis.
Journal ArticleDOI
Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review and mapping of emerging and overlapping challenges
TL;DR: The widespread presence of carbapenem and polymyxin resistance, including their overlap in 8 nations, represents a continuing risk and increases the threat of infections resistant to both and highlights the urgent need for sufficiently resourced robust antimicrobial resistance surveillance.
References
More filters
Journal ArticleDOI
Heart disease and stroke statistics-2015 update: A report from the American Heart Association
Dariush Mozaffarian,Emelia J. Benjamin,Alan S. Go,Donna K. Arnett,Michael J. Blaha,Mary Cushman,Sarah D. de Ferranti,Jean-Pierre Després,Heather J. Fullerton,Virginia J. Howard,Mark D. Huffman,Suzanne E. Judd,Brett M. Kissela,Daniel T. Lackland,Judith H. Lichtman,Lynda D. Lisabeth,Simin Liu,Rachel H. Mackey,David B. Matchar,Darren K. McGuire,Emile R. Mohler,Claudia S. Moy,Paul Muntner,Michael E. Mussolino,Khurram Nasir,Robert W. Neumar,Graham Nichol,Latha Palaniappan,Dilip K. Pandey,Mathew J. Reeves,Carlos J. Rodriguez,Paul D. Sorlie,Joel Stein,Amytis Towfighi,Tanya N. Turan,Salim S. Virani,Joshua Z. Willey,Daniel Woo,Robert W. Yeh,Melanie B. Turner +39 more
TL;DR: Mozaffarian, Dariush, Benjamin, Emelia J; Go, Alan S; Arnett, Donna K; Blaha, Michael J; Cushman, Mary; de Ferranti, Sarah; Despres, Jean-Pierre; Fullerton, Heather J; Howard, Virginia J; Huffman, Mark D; Judd, Suzanne E; Kissela, Brett M; Lackland, Daniel T; Lichtman, Judith H; Lisabeth, Lynda D; Liu, Simin; Mackey, Rachel H; Matchar, David B
Journal ArticleDOI
The annual impact of seasonal influenza in the US: Measuring disease burden and costs
Noelle-Angelique M. Molinari,Ismael R. Ortega-Sanchez,Mark L. Messonnier,William W. Thompson,Pascale M. Wortley,Eric Weintraub,Carolyn B. Bridges +6 more
TL;DR: The results highlight the enormous annual burden of influenza in the US, with hospitalization costs and lost productivity from missed work days and lost lives comprise the bulk of the economic burden.
Journal ArticleDOI
Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database
Jordi Rello,Daniel A. Ollendorf,Gerry Oster,Montserrat Vera-Llonch,Lisa A. Bellm,Rebecca Redman,Marin H. Kollef +6 more
TL;DR: It is demonstrated that VAP is a common nosocomial infection that is associated with poor clinical and economic outcomes and strategies to prevent the occurrence of VAP may not reduce mortality, but they may yield other important benefits to patients, their families, and hospital systems.
Anthropometric reference data for children and adults: United States, 2007-2010.
TL;DR: These latest NHANES data add to the knowledge about trends in child growth and development and trends in the distribution of body measurements, such as weight and height, in the U.S. population.
Journal ArticleDOI
Clinical and economic consequences of ventilator-associated pneumonia: a systematic review.
TL;DR: Ventilator-associated pneumonia occurs in a considerable proportion of patients undergoing mechanical ventilation and is associated with substantial morbidity, a two-fold mortality rate, and excess cost, and strategies that effectively prevent VAP are urgently needed.